Anti-C-KIT Antibody detects endogenous levels of total C-KIT protein.
KIT (proto-oncogene) is a type III receptor tyrosine kinase (RTK). It codes for a tyrosine kinase receptor (CD117). It is located on human chromosome 4q12.
The KIT (proto-oncogene receptor tyrosine kinase) gene is mapped to human chromosome 4q12. It encodes for a transmembrane glycoprotein that belongs to the receptor tyrosine kinases subclass III family.
Immunogen
The antiserum was produced against synthesized peptide derived from human c-Kit.
Immunogen Range: 688-737
Biochem/physiol Actions
KIT (proto-oncogene receptor tyrosine kinase) is considered to be an important hematopoietic growth factor receptor. It is known to exhibit tyrosine kinase activity that is associated with a variety of biologic processes, such as cell proliferation, survival, apoptosis, and motility. Downregulation of this gene is observed during the disease progression of multiple myeloma. Variation in the gene contributes to at least 2% of all melanomas and is most frequently observed in acral and mucosal melanomas. Mutations in KIT is associated with gastrointestinal stromal tumors.
KIT (proto-oncogene) participates in cell signal transduction. It also participates in the progression of hematopoietic stem cells, melanocytes, germ cells, mast cells and interstitial cells of Cajal. Mutations in KIT gene results in gastrointestinal stromal tumors.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients
Ceran F, et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology, 34(3), 226-226 (2017)
Loss of c-KIT expression in thyroid cancer cells.
Franceschi S, et al.
PLoS ONE, 12(3) (2017)
KIT Exon 11 Codons 557?558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors
Wang HC, et al.
Clinical Cancer Research, 22(14), 3477-3487 (2016)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
Guo J, et al.
Annals of Oncology, 28(6), 1380-1387 (2017)
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
Lux ML, et al.
The American Journal of Pathology, 156(3), 791-795 (2000)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.